NASDAQ · Biotechnology · USD

Cartesian Therapeutics, Inc. (RNAC) Stock Analysis

Cartesian Therapeutics, Inc. (RNAC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RNAC

$6.42

+$0.03 (+0.39%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RNAC with… →

RNAC Key Statistics

As of Oct 21, 2026

Trading

Open: $6.49
Previous Close: $6.40
Day's Range: 6.40–6.71
52-Week Range: 5.60–11.00
Volume: 105.94K
Beta: 0.72

Valuation

Market Cap: $194.24M
P/E Ratio: unprofitable
P/S ratio: 131.51
EPS (ttm): −5.78

Financials (FY)

Revenue (FY): $2.80M−92.81%
Net Income (FY): −$130.30M
Shares Outstanding: 30.26M
1-Year Return: −30.82%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 132.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RNAC closed at $6.42, −30.82% over 1 year.

Cartesian Therapeutics, Inc. (RNAC) has a market capitalization of $194.24M.

In fiscal 2025, RNAC reported revenue of $2.80M.

RNAC Stock Return by Calendar Year

Cartesian Therapeutics, Inc. (RNAC) 10-year return: what $10,000 became

1 year: $10,000 $6,918; −30.82%
5 years: $10,000 $542; −94.58%
10 years: $10,000 $128; −98.72%

If you had invested $10,000 in Cartesian Therapeutics, Inc. (RNAC) 10 years ago, at the close on October 21, 2016, it would have been worth $128 at the close on October 21, 2026: −98.72% in total, −35.32% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+53.61%−72.88%−10.96%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−10.96%
2025	−59.74%
2024	−13.35%
2023	−39.03%
2022	−65.34%
2021	+7.59%
2020	+27.31%
2019	−10.53%
2018	−72.88%
2017	−42.80%
2016 (partial year)	+53.61%

As of October 21, 2026.

RNAC Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$2.80M	−$130.30M	−4,658.6%
2024	$38.91M	−$77.42M	−199.0%
2023	$26.00M	−$219.71M	−844.9%
2022	$110.78M	$35.38M	31.9%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$2.80M	—	−$86.71M	−$130.30M	−4,658.6%
2024	$38.91M	—	−$36.32M	−$77.42M	−199.0%
2023	$26.00M	—	−$85.71M	−$219.71M	−844.9%
2022	$110.78M	—	$14.54M	$35.38M	31.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RNAC Valuation vs Biotechnology Median

Median of 608 stocks

Metric	RNAC	Biotechnology median	vs median
P/S ratio	131.51	13.30	9.9x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cartesian Therapeutics, Inc. (RNAC) is capitalised at $194.24M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 75 employees.

Over the past 52 weeks the price has ranged from $5.60 to $11.00. RNAC last closed at $6.42 on October 21, 2026. That is +$0.03 (+0.39%) against the previous close. The latest close sits 14.64% above that 52-week low.

Financial Health

In fiscal 2025, Cartesian Therapeutics, Inc. reported revenue of $2.80M. Against the prior fiscal year total of $38.91M, that is a change of −92.81%. The same year closed with a net loss of $130.30M. Trailing earnings per share are −5.78.

Across the 4 fiscal years on file, revenue moves from $110.78M in 2022 to $2.80M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 131.51 times revenue. On price-to-sales that is 9.9 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −30.82%. Across 10 years the annualized return works out at −35.32%. Beta against the wider market is reported at 0.72. Annualized volatility over the trailing 10 years is 90.71%.

Growth & Income

The record shows no dividend for RNAC.

2026 is still running; the total return is −10.96% year to date. Across the complete calendar years on file, 2020 returned +27.31% and 2018 returned −72.88%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Cartesian Therapeutics, Inc. (RNAC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Cartesian Therapeutics, Inc.	RNAC	$194.24M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Cartesian Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Visit website →